H241--Pharmacy Compounding Area Certification, for the Madison VA medical Center, Wisconsin
Plain-English Summary
The Veterans Affairs is looking for h241--pharmacy compounding area certification, for the madison va medical center, wisconsin. This is a service-disabled veteran-owned small business (sdvosb) set-aside (far 19.14) contract, meaning only qualifying small businesses can bid. Responses are due in 21 days (August 21, 2026). Work to be performed in Madison, Wisconsin.
Contract Details
- Solicitation #
- 36C25226Q0608
- Type
- Presolicitation
- NAICS Code
- 541380
- PSC Code
- H241
- Posted
- July 31, 2026
- Response Deadline
- August 21, 2026
Agency & Contact
- Department
- VETERANS AFFAIRS, DEPARTMENT OF
- Sub-agency
- VETERANS AFFAIRS, DEPARTMENT OF
- Office
- 252-NETWORK CONTRACT OFFICE 12 (36C252)
- Point of Contact
Who Should Bid
- Businesses classified under NAICS 541380
- Service-Disabled Veteran-Owned Small Businesses
- Must be registered in SAM.gov with active status
- Must have relevant past performance or capability statement
- Able to perform work in Wisconsin
Tips for Winning This Contract
- You have time to prepare a thorough response — use it for teaming arrangements or subcontracting
- Small business set-aside means less competition from large primes — your odds are better here
- Contact the contracting officer with questions BEFORE the deadline — they want to help qualified bidders
- Review the full solicitation documents on SAM.gov for detailed requirements
- Check if there's an industry day or Q&A session listed
Download attachments, full requirements, and submit your response on SAM.gov
Similar Opportunities
Microbiological Analysis of Potable Water Samples, Modoc NF
F103--SPS Critical Water Testing
CANCELLED 7/31/26 -- Mobile Hydrostatic Testing of SCOTT 3M Self-Contained Breathing Apparatus (SCBA) Bottles
Sources Sought - Four Blanket Purchase Agreement’s (BPA) for Construction Materials Testing Services Performed at Four Separate Locations and Surrounding Areas
Medicinal Chemistry Support for Therapeutic Development: Synthesis of HERV-K Protease Inhibitors